Another domestic pharmaceutical company will enter the tens of billions of dollars in the large-variety drug market

Recently, Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co.
, Ltd.
has entered the approval stage for the application of 4 types of generic Apixaban tablets, and is expected to become the 20th domestic pharmaceutical company approved for the product
.
It is understood that apixaban tablets are a highly selective and reversible factor Xa inhibitor, which is an oral anticoagulant, used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE)
.
The drug was jointly developed by Bristol-Myers Squibb and Pfizer under the trade name Elelto.
It was approved for marketing by the U.
S.
Food and Drug Administration (FDA) in December 2012
.
Statistics show that in 2020, the global sales of Apixaban will exceed 14 billion U.
S.
dollars
.
In China, it entered the Chinese market in 2013 and entered the medical insurance drug catalog in 2017
.
It is worth mentioning that the current apixaban tablets have been included in the third batch of national sourcing.
Therefore, the industry expects that if the evaluation can be successfully passed, the sales potential of Yangtze River's 4 generic drugs of apixaban tablets will be very considerable
.
It is understood that although Apixaban's domestic market is still small, it has been used in urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and physical drugstore terminals in Chinese cities in recent years.
Sales growth is very rapid
.
In 2019, the sales of apixaban in physical pharmacies in Chinese cities reached 8.
09 million yuan, an increase of 2596.
89% year-on-year; according to this trend, the market is expected to exceed 20 million yuan in 2021
.
However, it should be noted that as the market continues to expand and the number of companies entering the market continues to increase, competition in the drug market has become increasingly fierce
.
It is reported that, as of March this year, apixaban piece on the production of more than 10 companies approved and deemed too assessment, including Cologne medicine, IMC medicine, East Sunshine medicine, special times medicine, medicine, and other Qingfeng
.
In addition, dozens of pharmaceutical companies, including CSPC, Huahai Pharmaceutical, and Lepu Pharmaceutical, have submitted applications for the listing of apixaban tablets according to the new registration classification
.
For example, on February 6, Dongyang Sunshine issued an announcement that the holding subsidiary of Dongguan Yangzhikang Pharmaceutical Apixaban tablets was approved
.
Used for adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE)
.
In October, the "Apixaban Tablets (2.
5mg)" developed by CSPC Ouyi Pharmaceutical Co.
, Ltd.
has been approved for drug registration issued by the National Medical Products Administration of China, and the quality and efficacy of generic drugs are deemed to be consistent.
Sexual evaluation
.
From an overall point of view, at present, there is already a situation in which domestic leaders are competing for hegemony for the generic drug of apixaban, a blockbuster product
.
In the future, with the emergence of more and more generic drugs, it may be expected to quickly break the domestic monopoly of the original research and provide more drug options for the majority of patients
.
Although which pharmaceutical companies can rely on the generic drugs of this product to win in the domestic anticoagulation market is still unknown, the industry believes that the advantages of domestic domestic pharmaceutical companies for generic drugs are the product prices and channel advantages.
In these aspects The dominant companies may usher in more benefits in the future competition
.